Loading clinical trials...
Loading clinical trials...
A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)
Conditions
Interventions
Rituximab
Bortezomib
Locations
1
China
Qilu hospital, Shandong University
Jinan, Shandong, China
Start Date
March 1, 2018
Primary Completion Date
March 1, 2020
Completion Date
March 1, 2021
Last Updated
February 23, 2018
NCT05070845
NCT07039422
NCT07007962
NCT07104565
NCT06107582
NCT07362238
Lead Sponsor
Shandong University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions